Immuneering (IMRX)
(Delayed Data from NSDQ)
$9.26 USD
+0.25 (2.77%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $9.26 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
IMRX 9.26 +0.25(2.77%)
Will IMRX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for IMRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IMRX
Immuneering Stock Rises 21.7% on Supply Agreement With LLY
IMRX Stock Up on FDA's Orphan Drug Tag for Pancreatic Cancer Drug
IMRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for IMRX
New 52 Week Closing High appears for IMRX after 11.65% move
Is IMRX poised for gains? Boomer Buy Setup shows up after sinking 2.89%
IMRX forms Upper Bollinger Band Walk on September 16
IMRX forms Upper Bollinger Band Walk on September 15
Immuneering appoints Schall as Chairman of the Board